IRYO

The world’s first participatory, blockchain driven healthcare economy built on decentralising access to medical records. We’re driving the next generation of healthcare by standardising health-data,

About IRYO

Iryo Network aims to be a zero-knowledge health record storage platform, with an anonymous query interface, using blockchain permission controls for patient record access. Tokens will be used to incentivize end users’ permission for access to their records so as to enable artificial intelligence (AI) analysis and research; users will then be able to use the tokens to pay for medical services. IRYO also aims to provide open access to the platform (API) and open-source client code, using open standards to ensure interoperability, transparency and security.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain
Uniqueness/Advantages to competition: Geared toward enabling AI research and machine learning based on data in the network.

Token Sale Use of Blockchain

Product

3.2
Product
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

4.0
N/A
4 - Captivating.
Target User Base

Is it mass market or niche?

4.0
N/A
4 - Large audience / wide market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

3.0
N/A
3 - Some normal competition.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

3.0
N/A
3 - Partial, a novel approach or aspect.

Product

Iryo uses openEHR’s approach to health/medical data modeling and exchange, along with zero-knowledge data storage and EOS blockchain-based permission messages for providing access to records.
There is currently a publicly accessible active github repo, showing work on a pilot project for refugee camps. Complete beta/final blockchain development/testing for the platform is planned to occur after the ICO, and the public release is planned to occur in 2018 (see Roadmap).
There is appeal to the IRYO product, given the increasing demand for decentralized and secure storage of personal records in general and medical records in particular. The potential / target user-base will grow with natural population development (given the increasing need for medical services) and cryptocurrency adoption in the general population. There is currently some normal competition in the sector of decentralized medical marketplaces/blockchains, and blockchain competition will stiffen over time as cryptocurrency adoption continues.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain

Product Whitepaper

Use of Blockchain

3.6
Use of Blockchain
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

4.0
N/A
4 - Innovative use of blockchain technology.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

4.0
N/A
4 - Generally disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

3.0
N/A
3 - Issuing a custom token is justifiable.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

4.0
N/A
4 - Captivating.

Use of Blockchain

The project’s contribution to blockchain development is in creating a zero-knowledge health record storage platform, with an anonymous query interface. There is a disruptive advantage as the platform is aimed at enabling the encrypted and decentralized storage of medical records. Copies of encrypted health records will be stored on the Iryo cloud node, on home clinic storage nodes, and on end user devices, while blockchain tech (EOS) will be used for issuing permission messages, whereby end users provide various levels and models of access to their EHR. (“Iryo deems the importance of access control messages and history logs to be propagated near real-time in emergency situations as essential. Right now, this cannot be achieved/guaranteed on a network like Ethereum or Bitcoin.”)
There is need for a custom token, which allows for pricing and settlements as well as interaction on the platform. Institutions and clinics will have to stake IRYO tokens so as to cover the cost of storing EHR data for their patients; end users will be incentivized with tokens to allow queries on their data and will be able to use them to pay for medical services.
The contribution to the blockchain ecosystem is in developing a new decentralized platform for medical record storage and access.

Use of Blockchain Roadmap

Whitepaper

4.0
Whitepaper
Comprehensiveness

Does it cover the full scope of the problem and solution?

4.0
N/A
4 - Satisfactory coverage, well written.
Readability

Is it easy enough to understand?

4.0
N/A
4 - Easy to read and understand.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

4.0
N/A
4 - Informative disclosure.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

4.0
N/A
4 - Clear, well thought out, realistic.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

4.0
N/A
4 - Clear, well thought out, realistic.

Whitepaper

The whitepaper is well put together, professional and aesthetic, and contains a mixture of media and textual explanation. The whitepaper is 32 pages in length, and can be easily read and understood due to the amount media presented and efficient organization of the text. The whitepaper provides high level information and includes main sections which are each described in detail: Abstract, OpenEHR, Zero-knowledge Storage, Anynomous Query Interface, (public) Blockchain, Immutability of Medical Data, Why EOS, Token Utility, Cryptographic enforcement of permissions, Private Key Management, ZeroPass app, and Conclusion. The business and technology plans behind IRYO are detailed and concisely explained including textual and graphical explanations. References are provided in footnote form.

Whitepaper Compliance

Roadmap

2.8
Roadmap
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

3.0
N/A
3 - An overall plan, major milestones stated.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

3.0
N/A
3 - A trend with potential.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

3.0
N/A
3 - Imperfect but available, or using substitutes.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.

Roadmap

A milestone roadmap is given on a yearly basis. Obstacles lie ahead as final platform/blockchain development and public platform launch will occur after the ICO. The roadmap is vague and provides but does provide descriptions of the intermediate steps required to complete each milestone.

Roadmap:
2015 Preliminary Research
– executed preliminary research on establishing common interoperability between international medical systems.
2016 Seed
– provided initial capital and support to establish Iryo. The team began by validating several proof of concepts and pilot projects.
2017 Development
– The Iryo Network was introduced to the public in order to address common downfalls of inoperable medical systems.
2018 ICO + Production Grade Implementation
– Official crowdsale of Iryo tokens. Production grade, fully scalable implementation for Iryo partners.
2019 Iryo Public Release
– Integration of interoperable unified health records, zero-knowledge storage, and blockchain permissions.
2020 Network Expansion
– Iryo Network system support and adoption of value-added services. Design and execution of Iryo certified clinics.

Roadmap Company and Team

Compliance

2.0
Compliance
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

3.0
N/A
3 - Limited or uncertain use cases.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

2.0
N/A
2 - Minimal, superficial or hackneyed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

1.0
N/A
1 - None available.

Compliance

The IRYO-tokens have intrinsic value through their planned usage on the Iryo Network platform: staking by institutions and clinics and incentivization for end users to allow access to data. The token’s main utility is as a tradable financial instrument, as it is used specifically as a means of payment for storage, access to data, and medical services; however, the token also functions as a means for access to the network and ecosystem as a whole.
The token smart-contract infrastructure will be completed after the ICO, however there is an active github repo available for public review.
There is no legal disclaimer/review/agreement provided on the website or the whitepaper, although it is mentioned in the token summary that restrictions on the sale will apply to residents of China, South Korea, and the US (accredited investors ok).

Compliance Token Sale

Company and Team

3.4
Company and Team
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

4.0
N/A
4 - Established with some fundraising history.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

3.0
N/A
3 - Minimally sufficient.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

3.0
N/A
3 - Mostly assembled and committed.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

3.0
N/A
3 - Correlated to project requirements.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

4.0
N/A
4 - Good, sufficient for each aspect.

Company and Team

Iryo has an established team with 12 employees and 8 advisors.
The core team has experience in finance, investments, business development, product managment, security systems, programming, back-end development, UX/UI, marketing, and blockchain/cryptocurrency/smartcontract platform development.
The advisors to the project have experience primarily in healthcare, medicine, medical tech and related communications technology (eHealth, mHealth).
All team members have verifiable work experience credentials via LinkedIn profiles, however some profiles provide little information. Some members of the team appear to be dedicated to other projects outside of Iryo. Some of the core team members and advisors have previous experience with blockchain, cryptocurrency, or smart-contract projects, investing, and ICO consultation/launch.
Positives: The core team is well rounded and has previous experience in the field of blockchain, cryptocurrency, or smart contracts.
Negatives: Not all members are fully dedicated to the project.

Company and Team Product

Token Sale

2.6
Token Sale
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

3.0
N/A
3 - Justifiable.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

4.0
N/A
4 - Reasonable, sensible.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

1.0
N/A
1 - Not clear how funds will be used.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

3.0
N/A
3 - Sufficient company/community interest balance.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

2.0
N/A
2 - Minor exposure and interest, or ambivalent reception.

Token Sale

Iryo Token (IRYO)
Total Supply: 300 mil IRYO + 2% yearly inflation
Hard Cap: $26 million USD
Soft Cap: $8 milllion USD
Purchase: 1 IRYO = $0.11 USD

TOKEN DISTRIBUTION
80% Crowdsale
– 40% General Crowdsale
– 20% Window 1 with 20% Bonus
– 10% Window 2 with 10% Bonus
5% Airdrops
5% Private Sale
10% Team + Iryo

Social Media Presence & Following
There is little community engagment and reception.

Product

Iryo uses openEHR’s approach to health/medical data modeling and exchange, along with zero-knowledge data storage and EOS blockchain-based permission messages for providing access to records.
There is currently a publicly accessible active github repo, showing work on a pilot project for refugee camps. Complete beta/final blockchain development/testing for the platform is planned to occur after the ICO, and the public release is planned to occur in 2018 (see Roadmap).
There is appeal to the IRYO product, given the increasing demand for decentralized and secure storage of personal records in general and medical records in particular. The potential / target user-base will grow with natural population development (given the increasing need for medical services) and cryptocurrency adoption in the general population. There is currently some normal competition in the sector of decentralized medical marketplaces/blockchains, and blockchain competition will stiffen over time as cryptocurrency adoption continues.
Competitors: Proof Work, Mediledger, SimplyVital Health, Robomed Network, MedicalChain

Category Breakdown
Readiness

Is the product ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Appeal

How appealing is the product? How good or necessary is it? Does it have a distinct edge?

4.0
N/A
4 - Captivating.
Target User Base

Is it mass market or niche?

4.0
N/A
4 - Large audience / wide market.
Competition

Are there many other similar solutions or is this one of just a few, or even one of a kind?

3.0
N/A
3 - Some normal competition.
Innovation

How innovative or inventive is the product, either conceptually or technologically?

3.0
N/A
3 - Partial, a novel approach or aspect.
Product Score:
3.2

Use of Blockchain

The project’s contribution to blockchain development is in creating a zero-knowledge health record storage platform, with an anonymous query interface. There is a disruptive advantage as the platform is aimed at enabling the encrypted and decentralized storage of medical records. Copies of encrypted health records will be stored on the Iryo cloud node, on home clinic storage nodes, and on end user devices, while blockchain tech (EOS) will be used for issuing permission messages, whereby end users provide various levels and models of access to their EHR. (“Iryo deems the importance of access control messages and history logs to be propagated near real-time in emergency situations as essential. Right now, this cannot be achieved/guaranteed on a network like Ethereum or Bitcoin.”)
There is need for a custom token, which allows for pricing and settlements as well as interaction on the platform. Institutions and clinics will have to stake IRYO tokens so as to cover the cost of storing EHR data for their patients; end users will be incentivized with tokens to allow queries on their data and will be able to use them to pay for medical services.
The contribution to the blockchain ecosystem is in developing a new decentralized platform for medical record storage and access.

Category Breakdown
Blockchain Development

Is blockchain technology essential? Does it make the solution significantly different and better?

4.0
N/A
4 - Innovative use of blockchain technology.
Disruptive Blockchain Advantage

How disruptive is the introduction of blockchain technology into the product's market space?

4.0
N/A
4 - Generally disruptive.
Need for a Custom Token (vs. BTC or ETH)

Is the token essential or could it be done just as well or better with fiat or Bitcoin?

3.0
N/A
3 - Issuing a custom token is justifiable.
System Decentralization (besides token)

How decentralized is the system architecture other than the token (e.g., data collection, storage, access, and use, or decision making processes, etc.)?

3.0
N/A
3 - Hybrid; decentralized as far as circumstances allow.
Contribution to Blockchain Ecosystem

How compelling is the solution's contribution to the evolution of blockchain infrastructure and economy?

4.0
N/A
4 - Captivating.
Use of Blockchain Score:
3.6

Whitepaper

The whitepaper is well put together, professional and aesthetic, and contains a mixture of media and textual explanation. The whitepaper is 32 pages in length, and can be easily read and understood due to the amount media presented and efficient organization of the text. The whitepaper provides high level information and includes main sections which are each described in detail: Abstract, OpenEHR, Zero-knowledge Storage, Anynomous Query Interface, (public) Blockchain, Immutability of Medical Data, Why EOS, Token Utility, Cryptographic enforcement of permissions, Private Key Management, ZeroPass app, and Conclusion. The business and technology plans behind IRYO are detailed and concisely explained including textual and graphical explanations. References are provided in footnote form.

Category Breakdown
Comprehensiveness

Does it cover the full scope of the problem and solution?

4.0
N/A
4 - Satisfactory coverage, well written.
Readability

Is it easy enough to understand?

4.0
N/A
4 - Easy to read and understand.
Transparency

Does it candidly describe and disclose where the project now stands, how much exists and how much still needs to be done, etc.?

4.0
N/A
4 - Informative disclosure.
Business Plan Presentation

Does it contain a viable, comprehensive business plan?

4.0
N/A
4 - Clear, well thought out, realistic.
Technology Presentation

Does it present a well thought out technological architecture? Does it address implementational challenges?

4.0
N/A
4 - Clear, well thought out, realistic.
Whitepaper Score:
4.0

Roadmap

A milestone roadmap is given on a yearly basis. Obstacles lie ahead as final platform/blockchain development and public platform launch will occur after the ICO. The roadmap is vague and provides but does provide descriptions of the intermediate steps required to complete each milestone.

Roadmap:
2015 Preliminary Research
– executed preliminary research on establishing common interoperability between international medical systems.
2016 Seed
– provided initial capital and support to establish Iryo. The team began by validating several proof of concepts and pilot projects.
2017 Development
– The Iryo Network was introduced to the public in order to address common downfalls of inoperable medical systems.
2018 ICO + Production Grade Implementation
– Official crowdsale of Iryo tokens. Production grade, fully scalable implementation for Iryo partners.
2019 Iryo Public Release
– Integration of interoperable unified health records, zero-knowledge storage, and blockchain permissions.
2020 Network Expansion
– Iryo Network system support and adoption of value-added services. Design and execution of Iryo certified clinics.

Category Breakdown
Concreteness

Is there a concrete and practical development plan (vs. just a conceptual vision)?

3.0
N/A
3 - An overall plan, major milestones stated.
Feasibility

Is the development plan realistic? Is it based on reasonable goals and timelines?

3.0
N/A
3 - Optimistic.
Vision

Is there a larger, long-term vision?

3.0
N/A
3 - A trend with potential.
Dependencies (services or capabilities)

How available, operational, or trusted are the other systems or capabilities on which the project relies?

3.0
N/A
3 - Imperfect but available, or using substitutes.
Current Position

Where is the project now, relative to its vision and plans?

2.0
N/A
2 - Critical obstacles ahead.
Roadmap Score:
2.8

Compliance

The IRYO-tokens have intrinsic value through their planned usage on the Iryo Network platform: staking by institutions and clinics and incentivization for end users to allow access to data. The token’s main utility is as a tradable financial instrument, as it is used specifically as a means of payment for storage, access to data, and medical services; however, the token also functions as a means for access to the network and ecosystem as a whole.
The token smart-contract infrastructure will be completed after the ICO, however there is an active github repo available for public review.
There is no legal disclaimer/review/agreement provided on the website or the whitepaper, although it is mentioned in the token summary that restrictions on the sale will apply to residents of China, South Korea, and the US (accredited investors ok).

Category Breakdown
Token Utility (value through usage)

How much use is there for the token itself (regardless of its value as an investment vehicle)?

3.0
N/A
3 - Limited or uncertain use cases.
Token as Security (tradable instrument)

How valuable is the token as an investment vehicle or financial instrument?

2.0
N/A
2 - Primarily, with few additional rights.
Token/Smart-Contract Readiness

Is the blockchain infrastructure of the project ready for use? Is there a working prototype or MVP? How long until it is operational?

2.0
N/A
2 - Proof of concept or test platform.
Attention to Compliance Issues

How much attention is given to compliance (via token and ecosystem design, token sale participation, etc.)? Is this issue addressed directly and coherently?

2.0
N/A
2 - Minimal, superficial or hackneyed.
Legal Review/Risk Assessment

What kind of legal documentation (reviews or agreements) and risk assessment are provided?

1.0
N/A
1 - None available.
Compliance Score:
2.0

Company and Team

Iryo has an established team with 12 employees and 8 advisors.
The core team has experience in finance, investments, business development, product managment, security systems, programming, back-end development, UX/UI, marketing, and blockchain/cryptocurrency/smartcontract platform development.
The advisors to the project have experience primarily in healthcare, medicine, medical tech and related communications technology (eHealth, mHealth).
All team members have verifiable work experience credentials via LinkedIn profiles, however some profiles provide little information. Some members of the team appear to be dedicated to other projects outside of Iryo. Some of the core team members and advisors have previous experience with blockchain, cryptocurrency, or smart-contract projects, investing, and ICO consultation/launch.
Positives: The core team is well rounded and has previous experience in the field of blockchain, cryptocurrency, or smart contracts.
Negatives: Not all members are fully dedicated to the project.

Category Breakdown
Company Stage and Foundation

Is the company already established? Has it raised funds before? Is it mature?

4.0
N/A
4 - Established with some fundraising history.
Background of Lead Team Members

Do we know who they are? Do they have LinkedIn profiles? Do they have solid, relevant backgrounds?

3.0
N/A
3 - Minimally sufficient.
Team Assembly and Commitment

Is a solid, fully committed core team in place? Do they have online (e.g. LinkedIn) profiles showing sufficient relevant experience? Is their participation transparent?

3.0
N/A
3 - Mostly assembled and committed.
Team Skill Set Relevance

Does the amount of talent and skill in each area seem to fit the project requirements?

3.0
N/A
3 - Correlated to project requirements.
Team Skill Set Balance

Is the team well-rounded (biz/tech/blockchain)? Is there sufficient talent and skill in all areas of required development?

4.0
N/A
4 - Good, sufficient for each aspect.
Company and Team Score:
3.4

Token Sale

Iryo Token (IRYO)
Total Supply: 300 mil IRYO + 2% yearly inflation
Hard Cap: $26 million USD
Soft Cap: $8 milllion USD
Purchase: 1 IRYO = $0.11 USD

TOKEN DISTRIBUTION
80% Crowdsale
– 40% General Crowdsale
– 20% Window 1 with 20% Bonus
– 10% Window 2 with 10% Bonus
5% Airdrops
5% Private Sale
10% Team + Iryo

Social Media Presence & Following
There is little community engagment and reception.

Category Breakdown
Raise Amount Max

Is there a clear cap? Is the maximum raise amount modestly sufficient (as opposed to either greedy or insufficient)?

3.0
N/A
3 - Justifiable.
Raise Amount Min

Is the minimum raise reasonable considering the development plan? Are there raise-amount dependent milestones?

4.0
N/A
4 - Reasonable, sensible.
Fund Allocation

Is fund distribution and allocation reasonable and justified?

1.0
N/A
1 - Not clear how funds will be used.
Token Allocation

Is the ratio of tokens sold to those kept reasonable? Does it prevent the company from having too much control?

3.0
N/A
3 - Sufficient company/community interest balance.
Media Presence and Following

Is the sale being talked about in Reddit, Bitcointalk, Social Media, Medium, etc.? Is information available and accessible? Is there interest?

2.0
N/A
2 - Minor exposure and interest, or ambivalent reception.
Token Sale Score:
2.6

Use this code to share the ratings on your website